trending Market Intelligence /marketintelligence/en/news-insights/trending/hxR1Qy7oblp6HJKSjt03vA2 content esgSubNav
In This List

Orexigen prevails in patent litigation against Teva unit

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Video

S&P Capital IQ Pro | Powering Your Edge

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Orexigen prevails in patent litigation against Teva unit

Orexigen Therapeutics Inc.'s weight-loss therapy Contrave will continue to have market exclusivity after a U.S. court favored the company in its patent litigation lawsuit against Actavis Laboratories FL Inc.

The U.S. District Court for the District of Delaware upheld the validity of all the patents involved in the case, with exclusivity through 2030.

Actavis Laboratories, a unit of Teva Pharmaceutical Industries Ltd., was looking to market a generic version of the drug.